The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling

NCT ID: NCT06605300

Last Updated: 2025-10-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-02
• Study Completion Date: 2025-08-12

Brief Summary

The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.

Detailed Description

A double-blinded, placebo-controlled, between-subject design is employed in this study. In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo. (1) 15-minute resting-state EEG data are collected 35 minutes after treatment. (2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), and Adult ADHD Self-Report Scale (ASRS-v1.1). Participants are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before resting state and after the tasks. Three blood samples (5 ml) are collected into 6 ml ETDA tubes when participants just arrive, before resting state recording and after all of the tasks.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

oxytocin

A single dose of 24 international units (IU) of oxytocin will be administered with 3 puffs of treatment to each nostril.

Group Type: EXPERIMENTAL

Intranasal Oxytocin (IN-OXT)

Intervention Type: DRUG

Subject assigned to receive intranasal administration of oxytocin (24 IU).

vasopressin

A single dose of 20 international units (IU) of vasopressin will be administered with 3 puffs of treatment to each nostril.

Group Type: EXPERIMENTAL

Intranasal Vasopressin (AVP)

Intervention Type: DRUG

Subjects assigned to receive intranasal administration of vasopressin (20 IU).

placebo

A single dose of placebo will be administered with 3 puffs of treatment to each nostril.

Group Type: PLACEBO_COMPARATOR

Intranasal Placebo

Intervention Type: DRUG

Subjects assigned to receive intranasal administration of placebo.

Interventions

Intranasal Oxytocin (IN-OXT)

Subject assigned to receive intranasal administration of oxytocin (24 IU).

Intervention Type: DRUG

Intranasal Vasopressin (AVP)

Subjects assigned to receive intranasal administration of vasopressin (20 IU).

Intervention Type: DRUG

Intranasal Placebo

Subjects assigned to receive intranasal administration of placebo.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy subjects without past or current psychiatric or neurological disorders.

Exclusion Criteria

• History of head injury.
• Pregnant,menstruating,taking oral contraceptives.
• Medical or psychiatric illness.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Electronic Science and Technology of China

OTHER

Sponsor Role: lead

Responsible Party

Shuxia Yao

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Shuxia Yao, Dr

Role: PRINCIPAL_INVESTIGATOR

University of Electronic Science and Technology of China

Locations

University of Electronic Science and Technology of China

Chengdu, Chengdu, China

University of Electronic Science and Technology of China (UESTC)

Chengdu, Sichuan, China

Countries

China

Other Identifiers

UESTC-neuSCAN-96

Identifier Type: -

Identifier Source: org_study_id